Merrimack Pharmaceuticals

company

About

Merrimack Pharmaceuticals discovers, designs and develops therapies for the treatment of diseases in the areas of autoimmunity and cancer.

  • 51 - 100

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
$25M
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2000
Number Of Employee
51 - 100
Operating Status
Active

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, design, and development of therapies for the treatment of diseases in the areas of autoimmunity and cancer. It develops MM-093, a human alpha-fetoprotein for the treatment of patients with rheumatoid arthritis and psoriasis; and MM-121, a human monoclonal antibody and therapeutic to block signaling of the ErbB3 receptor. Merrimack Pharmaceuticals, Inc. was formerly known as Atlantic BioPharmaceuticals, Inc. The company was founded in 1993 and is based in Cambridge, Massachusetts.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
7
$232.30M
Merrimack Pharmaceuticals has raised a total of $232.30M in funding over 2 rounds. Their latest funding was raised on Jul 2, 2018 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 2, 2018 Post-IPO Debt $25M 1 Hercules Capital Detail
Apr 14, 2011 Private Equity(PE) $77M 1 Detail
Apr 3, 2006 Series E $65M 1 Detail
Jun 20, 2005 Debt Financing $9M 1 Hercules Capital Detail
Apr 20, 2005 Series D $28.30M 1 Detail

Investors

Number of Lead Investors
Number of Investors
3
4
Merrimack Pharmaceuticals is funded by 4 investors. Hercules Capital and National Institutes of Health are the most recent investors.
Investor Name Lead Investor Funding Round
Hercules Capital Yes Post-IPO Debt
National Institutes of Health Yes Grant
WT Investment Advisors Fund Private Equity(PE)
Wharton Capital Series C